You do not have permission to edit this page, for the following reasons:

This IP address has been blocked from editing Wikipedia.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

The IP address or range 3.95.0.0/16 has been blocked (disabled) by ‪Blablubbs‬ for the following reason(s):

The IP address that you are currently using has been blocked because it is believed to be a web host provider or colocation provider. To prevent abuse, web hosts and colocation providers may be blocked from editing Wikipedia.
You will not be able to edit Wikipedia using a web host or colocation provider because it hides your IP address, much like a proxy or VPN.
We recommend that you attempt to use another connection to edit. For example, if you use a proxy or VPN to connect to the internet, turn it off when editing Wikipedia. If you edit using a mobile connection, try using a Wi-Fi connection, and vice versa. If you are using a corporate internet connection, switch to a different Wi-Fi network. If you have a Wikipedia account, please log in.
If you do not have any other way to edit Wikipedia, you will need to request an IP block exemption.

How to appeal if you are confident that your connection does not use a colocation provider's IP address:
If you are confident that you are not using a web host, you may appeal this block by adding the following text on your talk page: ((unblock|reason=Caught by a colocation web host block but this host or IP is not a web host. My IP address is _______. Place any further information here. ~~~~)). You must fill in the blank with your IP address for this block to be investigated. Your IP address can be determined here. Alternatively, if you wish to keep your IP address private you can use the unblock ticket request system. There are several reasons you might be editing using the IP address of a web host or colocation provider (such as if you are using VPN software or a business network); please use this method of appeal only if you think your IP address is in fact not a web host or colocation provider.

Administrators: The IP block exemption user right should only be applied to allow users to edit using web host in exceptional circumstances, and requests should usually be directed to the functionaries team via email. If you intend to give the IPBE user right, a CheckUser needs to take a look at the account. This can be requested most easily at SPI Quick Checkuser Requests. Unblocking an IP or IP range with this template is highly discouraged without at least contacting the blocking administrator.

This block will expire on 08:49, 2 November 2024.

Even when blocked, you will usually still be able to edit your user talk page, as well as email administrators and other editors.

For information on how to proceed, please read the FAQ for blocked users and the guideline on block appeals. The guide to appealing blocks may also be helpful.

Other useful links: Blocking policy · Help:I have been blocked
Your IP address is in a range that has been blocked on all Wikimedia Foundation wikis. The block was made by ‪Jon Kolbert‬. The reason given is Open proxy/Webhost: See the help page if you are affected .
- Start of block: 05:35, 21 February 2024
- Expiry of block: 05:35, 21 February 2029
Your current IP address is 3.95.152.51. The blocked range is 3.95.0.0/16. Please include all above details in any queries you make. If you believe you were blocked by mistake, you can find additional information and instructions in the No open proxies global policy. Otherwise, to discuss the block please post a request for review on Meta-Wiki. You could also send an email to the stewards VRT queue at stewards@wikimedia.org including all above details.

You can view and copy the source of this page:

((Navbox
 | name = Targeted cancer therapeutic agents
 | title = [[Targeted cancer therapy]] / [[Antineoplastic|antineoplastic agents]] ([[ATC code L01|L01]])
 | state = (({state<includeonly>|autocollapse</includeonly>))}
 | listclass = hlist

 | group1 = [[Cancer immunotherapy|CI]] [[Monoclonal antibody therapy|monoclonal antibodies]] ("-mab")
 | list1 = ((Navbox|child

   | group1 = [[Receptor tyrosine kinase]]
   | list1 =
* [[ErbB]]: ''[[Epidermal growth factor receptor|HER1/EGFR]]'' ([[Cetuximab]]
* [[Panitumumab]])
* ''[[HER2/neu]]'' ([[Pertuzumab]], [[Trastuzumab]] ([[Trastuzumab/hyaluronidase|+hyaluronidase]])
* [[Trastuzumab emtansine]]
* [[Trastuzumab deruxtecan]])

   | group2 = Others for solid tumors
   | list2 =
* ''[[EpCAM]]'' ([[Catumaxomab]]
* [[Edrecolomab]])
* ''[[Vascular endothelial growth factor A|VEGF-A]]'' ([[Bevacizumab]])

   | group3 = [[Leukemia]]/[[lymphoma]]
   | list3 =
* [[Lymphatic system|lymphoid]]: ''[[CD3 (immunology)|CD3]]'' ([[Glofitamab]], [[Elranatamab]], [[Mosunetuzumab]]), ''[[CD20]]'' ([[Glofitamab]]
* [[Ibritumomab tiuxetan|Ibritumomab]]
* [[Mosunetuzumab]]
* [[Obinutuzumab]]
* [[Ofatumumab]]
* [[Rituximab]]
* [[Tositumomab]]), ''[[CD30]]'' ([[Brentuximab vedotin|Brentuximab]]), ''[[CD52]]'' ([[Alemtuzumab]])

* [[myeloid]]: ''[[CD33]]'' ([[Gemtuzumab ozogamicin]])

   | group4 = Other
   | list4 =
* [[Amivantamab]]
* [[Atezolizumab]]
* [[Avelumab]]
* [[Belantamab mafodotin]]
* [[Bermekimab]]
* [[Blinatumomab]]
* [[Cemiplimab]]
* [[Daratumumab]]
* [[Dinutuximab beta]]
* [[Dostarlimab]]
* [[Durvalumab]]
* [[Elotuzumab]]
* [[Enfortumab vedotin]]
* [[Inotuzumab ozogamicin]]
* [[Ipilimumab]]
* [[Isatuximab]]
* [[Mirvetuximab soravtansine]]
* [[Mogamulizumab]]
* [[Moxetumomab pasudotox]]
* [[Necitumumab]]
* [[Nivolumab]]
* [[Olaratumab]]
* [[Pembrolizumab]]
* [[Polatuzumab vedotin]]
* [[Ramucirumab]]
* [[Retifanlimab]]
* [[Tafasitamab]]
 ))

 | group2 = [[Tyrosine kinase inhibitor]]s ("-nib")
 | list2 = ((Navbox|child
   | evenodd = swap

   | group1 = [[Receptor tyrosine kinase]]
   | list1 =
* [[ErbB]]: ''[[Epidermal growth factor receptor|HER1/EGFR]]'' ([[Afatinib]]
* [[Brigatinib]]
* [[Dacomitinib]]
* [[Erlotinib]]
* [[Gefitinib]]
* [[Icotinib]]
* [[Mobocertinib]]
* [[Olmutinib]]
* [[Osimertinib]]
* [[Rociletinib]]
* [[Vandetanib]])

* ''HER1/EGFR and [[HER2/neu]]''
** [[Lapatinib]]
** [[Neratinib]]
** [[Tucatinib]]

* [[RTK class III]]: ''[[CD117|C-kit]] and [[Platelet-derived growth factor receptor|PDGFR]]'' ([[Avapritinib]]
* [[Axitinib]]
* [[Masitinib]]
* [[Pazopanib]]
* [[Ripretinib]]
* [[Sorafenib]]
* [[Sunitinib]]
* [[Toceranib]])
* ''[[CD135|FLT3]]'' ([[Lestaurtinib]], [[Gilteritinib]] (AXL, ALK, LTK))

* ''[[VEGF receptors|VEGFR]]''
** [[Axitinib]]
** [[Cediranib]]
** [[Fruquintinib]]
** [[Lenvatinib]]
** [[Nintedanib]]
** [[Pazopanib]]
** [[Regorafenib]]
** [[Semaxanib]]
** [[Sorafenib]]
** [[Sunitinib]]
** [[Tivozanib]]
** [[Toceranib]]
** [[Vandetanib]]

* ''[[Anaplastic lymphoma kinase|ALK]]''
** [[Alectinib]]
** [[Brigatinib]]
** [[Ceritinib]]

*''[[RET_proto-oncogene|RET]] inhibitors:'' [[Entrectinib]] (ALK, ROS1, NTRK), [[Futibatinib]] (FGFR2), [[Infigratinib]], [[Larotrectinib]] (NTRK), [[Pemigatinib]] (FGFR), [[Pralsetinib]], [[Repotrectinib]] (ROS1, TRK, ALK), [[Selpercatinib]] (VEGFR, FGFR), [[Vandetanib]] (VEGFR, EGFR).

*''[[C-Met|c-MET]] inhibitors:'' [[Cabozantinib]] (VEGFR), [[Capmatinib]], [[Crizotinib]] (ALK)

   | group2 = [[Non-receptor tyrosine kinase|Non-receptor]]
   | list2 =
* ''[[Bcr-abl fusion protein|bcr-abl]]''
** [[Asciminib]]
** [[Bosutinib]]
** [[Dasatinib]]
** [[Imatinib]]
** [[Nilotinib]]
** [[Ponatinib]]
** [[Radotinib]]

* ''[[Src (gene)|Src]]'' ([[Bosutinib]]
* [[Dasatinib]])

* ''[[Janus kinase]]''
** [[Baricitinib]]
** [[Fedratinib]]
** [[Filgotinib]]
** [[Lestaurtinib]]
** [[Momelotinib]]
** [[Pacritinib]]
** [[Ruxolitinib]]

* ''[[Mitogen-activated protein kinase kinase|MAP2K]]''
** [[Binimetinib]]
** [[Cobimetinib]]
** [[Selumetinib]]
** [[Trametinib]]

* ''[[EML4]]-[[Anaplastic lymphoma kinase|ALK]]''
** [[Crizotinib]]
** [[Entrectinib]]
** [[Lorlatinib]]

* ''[[Bruton's tyrosine kinase|Bruton's]]''
** [[Acalabrutinib]]
** [[Ibrutinib]]
** [[Pirtobrutinib]]
** [[Zanubrutinib]]
 ))

<!-- group3 omitted to preserve alternating striping -->

 | group4 = Other
 | list4 =
* ''[[fusion protein]] against [[Vascular endothelial growth factor|VEGF]]'' ([[Aflibercept]])
* ''[[proapoptotic]] peptide against [[ANXA2]] and [[prohibitin]]'' ([[Adipotide]])
* ''[[exotoxin]] against [[Interleukin 2|IL-2]]'' ([[Denileukin diftitox]])
* ''[[mTOR inhibitor]]s''
** [[Everolimus]]
** [[Ridaforolimus]]
** [[Temsirolimus]]
* ''[[Hedgehog signaling pathway|hedgehog]] inhibitors''
** [[Glasdegib]]
** [[Sonidegib]]
** [[Vismodegib]]
* ''[[CDK inhibitor]]s''
** [[Abemaciclib]]
** [[Dalpiciclib]]
** [[Palbociclib]]
** [[Ribociclib]]
** [[Trilaciclib]]
* ''[[KRAS]] inhibitors''
** [[Adagrasib]]
** [[Sotorasib]]
* [[Cabozantinib]]
* [[Capmatinib]]
* [[Entrectinib]]
* [[Erdafitinib]]
* [[Gilteritinib]]
* [[Larotrectinib]]
* [[Lenvatinib]]
* [[Masitinib]]
* [[Midostaurin]]
* [[Nintedanib]]
* [[Pazopanib]]
* [[Pemigatinib]]
* [[Pexidartinib]]
* [[Quizartinib]]
* [[Regorafenib]]
* [[Ripretinib]]
* [[Sorafenib]]
* [[Sunitinib]]
* [[Tebentafusp]]
* [[Tepotinib]]
* [[Vandetanib]]
* [[Venetoclax]]

))<noinclude>
((Documentation|content=
((Collapsible option))
[[Category:Drug templates by ATC]]
[[Category:Oncology navigational boxes]]
))</noinclude>

Pages transcluded onto the current version of this page (help):

Template:Collapsible option (view source) (template editor protected)
Template:Documentation (view source) (template editor protected)
Template:Hlist/styles.css (view source) (protected)
Template:Navbox (view source) (template editor protected)
Template:Para (view source) (template editor protected)
Template:Param value (view source) (template editor protected)
Template:Replace (view source) (protected)
Template:Template other (view source) (protected)
Module:Arguments (view source) (protected)
Module:Color contrast (view source) (template editor protected)
Module:Color contrast/colors (view source) (template editor protected)
Module:Documentation (view source) (template editor protected)
Module:Documentation/config (view source) (template editor protected)
Module:Documentation/styles.css (view source) (template editor protected)
Module:Navbar (view source) (protected)
Module:Navbar/configuration (view source) (protected)
Module:Navbar/styles.css (view source) (protected)
Module:Navbox (view source) (template editor protected)
Module:Navbox/configuration (view source) (template editor protected)
Module:Navbox/styles.css (view source) (template editor protected)
Module:String (view source) (protected)

Return to Template:Targeted cancer therapeutic agents.

Retrieved from "https://en.wikipedia.org/wiki/Template:Targeted_cancer_therapeutic_agents"